Dhillon Jaydeep, Maguire James A, Kraeutler Matthew J
Samaritan Health Services, Department of Orthopedics, Corvallis, OR 97330, USA.
St. Joseph's University Medical Center, Department of Orthopaedic Surgery, Paterson, NJ 07503, USA.
Osteoarthr Cartil Open. 2025 Apr 9;7(2):100608. doi: 10.1016/j.ocarto.2025.100608. eCollection 2025 Jun.
To systematically review randomized controlled trials (RCTs) to compare clinical outcomes of stromal cell-based injection therapies versus other non-operative treatment modalities for the treatment of knee osteoarthritis (OA).
A systematic review was performed by searching PubMed, Cochrane Library, and EMBASE to locate RCTs, published since 2019, comparing stromal cell-based injection therapies versus other non-operative modalities for the treatment of knee OA. The search terms used were: .
Seventeen studies (all Level I evidence) were included in this review with 972 patients undergoing treatment with stromal cell-based therapy (Intervention Group) and 651 patients in the control group (Control Group). Among the 17 studies, 7 used autologous adipose-derived mesenchymal stromal cells (MSCs) (ADMSCs), 2 studies used allogeneic ADMSCs, 4 used autologous bone marrow-derived MSCs (BMMSCs), 1 used allogeneic BMMSCs, 1 used allogeneic placental MSCs, 1 used umbilical cord-derived MSCs (UCMSCs), and 1 study used autologous ADMSCs, BMMSCs, or allogeneic UCMSCs. All but 3 studies reported significantly better clinical or radiological outcomes in the Intervention Group at final follow-up. A total of 5 and 3 studies reported adverse events occurring in the Intervention and the Control groups, respectively, but they were all self-limiting.
Patients undergoing treatment of knee OA with MSCs might be expected to experience improvements in clinical and radiological outcomes in comparison to other non-operative modalities. Additional studies with mid-to long-term outcomes are needed to better determine the efficacy and safety of MSCs for the treatment of knee OA.
系统评价随机对照试验（RCT），以比较基于基质细胞的注射疗法与其他非手术治疗方式治疗膝关节骨关节炎（OA）的临床疗效。
通过检索PubMed、Cochrane图书馆和EMBASE进行系统评价，以查找2019年以来发表的比较基于基质细胞的注射疗法与其他非手术方式治疗膝关节OA的RCT。使用的检索词为：
本评价纳入了17项研究（均为I级证据），972例患者接受基于基质细胞的治疗（干预组），651例患者为对照组。在这17项研究中，7项使用自体脂肪来源的间充质基质细胞（MSCs）（ADMSCs），2项研究使用异体ADMSCs，4项使用自体骨髓来源的MSCs（BMMSCs），1项使用异体BMMSCs，1项使用异体胎盘MSCs，1项使用脐带来源的MSCs（UCMSCs），1项研究使用自体ADMSCs、BMMSCs或异体UCMSCs。除3项研究外，所有研究均报告干预组在最终随访时临床或影像学结局显著更好。分别有5项和3项研究报告干预组和对照组发生不良事件，但均为自限性。
与其他非手术方式相比，接受MSCs治疗膝关节OA的患者可能在临床和影像学结局方面有所改善。需要更多具有中长期结局的研究，以更好地确定MSCs治疗膝关节OA的疗效和安全性。
